Literature DB >> 13585283

Hypersensitivity myocarditis occurring with sulfamethoxypyridazine therapy.

A J BLANCHARD, G A MERTENS.   

Abstract

Entities:  

Keywords:  ALLERGY; MYOCARDITIS/etiology and pathogenesis; SULFONAMIDES/injurious effects

Mesh:

Substances:

Year:  1958        PMID: 13585283      PMCID: PMC1830223     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


× No keyword cloud information.
  3 in total

1.  The Pathology of Sulfonamide Allergy in Man.

Authors:  R H More; G C McMillan; G L Duff
Journal:  Am J Pathol       Date:  1946-07       Impact factor: 4.307

2.  Hypersensitivity in the Pathogenesis of the Histopathologic Changes Associated with Sulfonamide Chemotherapy.

Authors:  A J French
Journal:  Am J Pathol       Date:  1946-07       Impact factor: 4.307

3.  Interstitial Myocarditis Following the Clinical and Experimental Use of Sulfonamide Drugs.

Authors:  A J French; C V Weller
Journal:  Am J Pathol       Date:  1942-01       Impact factor: 4.307

  3 in total
  6 in total

1.  Congestive heart failure caused by sensitivity to diphenylhydantoin (diiantin sodium).

Authors:  S A CARLEN
Journal:  Can Med Assoc J       Date:  1959-05-01       Impact factor: 8.262

2.  Fatal case of Stevens-Johnson syndrome after sulphamethoxypyridazine treatment.

Authors:  K E MELVIN; R N HOWIE
Journal:  Br Med J       Date:  1961-09-30

3.  Cardiomyopathy as a complication of sulphonamide therapy.

Authors:  E T MacSearraigh; K M Patel
Journal:  Br Med J       Date:  1968-07-06

4.  [Electrocardiographic examination in patients with skin diseases].

Authors:  R Denk
Journal:  Arch Kreislaufforsch       Date:  1969-10

5.  A case of fatal peri-partum cardiomyopathy.

Authors:  R A Hughes; P Kapur; G C Sutton; M Honey
Journal:  Br Heart J       Date:  1970-03

6.  Sulfamethoxypyridazine (Kynex).

Authors:  R G Warminton
Journal:  Can Med Assoc J       Date:  1959-05-01       Impact factor: 8.262

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.